loading

Gyre Therapeutics Inc Borsa (GYRE) Ultime notizie

pulisher
May 30, 2025

Gyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis Trials - MSN

May 30, 2025
pulisher
May 29, 2025

Gyre Therapeutics Closes $23 Million Public Offering - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - TradingView

May 29, 2025
pulisher
May 29, 2025

Northern Trust Corp Buys 8,624 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

May 29, 2025
pulisher
May 27, 2025

What's Behind The Big Stock Moves? GYRE, KYTX, TNGX... - Nasdaq

May 27, 2025
pulisher
May 27, 2025

MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday - Benzinga

May 27, 2025
pulisher
May 26, 2025

GNI Group Prices Public Offering at $20 Million to Fund Clinical Trials - marketscreener.com

May 26, 2025
pulisher
May 25, 2025

Gyre Therapeutics slumps 16%, prices $20M stock offering - MSN

May 25, 2025
pulisher
May 25, 2025

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – What’s Next? - Defense World

May 25, 2025
pulisher
May 23, 2025

Gyre Therapeutics announces new stock offering By Investing.com - Investing.com Nigeria

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics (GYRE) Launches $20 Million Public Offering - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics Announces Stock Offering Agreement - TipRanks

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics announces new stock offering - Investing.com

May 23, 2025
pulisher
May 23, 2025

GYRE Trading Resumes After Temporary Halt | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Trading Halted for Catalyst Biosciences (GYRE) Due to Volatility | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics commences underwritten public offering - MSN

May 23, 2025
pulisher
May 23, 2025

Gyre Therapeutics Prices $20 Million Common Stock Offering - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

GYRE Announces Pricing Below Previous Closing Price | GYRE Stock News - GuruFocus

May 23, 2025
pulisher
May 22, 2025

Gyre Therapeutics Raises $20M in Public Offering to Advance MASH Liver Fibrosis Treatment - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Pricing Of $20 Million Public Offering Of Common Stock At $9.00 Per Share - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - Yahoo Finance

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Meets Primary Endpoint for Compound to Treat Liver Fibrosis - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics (GYRE) Achieves Key Milestone with Hydronidone in Phase 3 Trial | GYRE Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics tumbles after stock offering launch - TradingView

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics launches public stock offering By Investing.com - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics (GYRE) Launches Public Offering to Fund Clinical Trial and Growth | GYRE Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Announces Commencement of Underwritten Public Offering of Common Stock - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Gyre Therapeutics Seeks Fresh Capital: Public Offering to Accelerate Phase 2 MASH Treatment Trial - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Breakthrough in Liver Disease: Gyre's Phase 3 Drug Achieves 53% Fibrosis Regression, First-in-Class Potential - Stock Titan

May 22, 2025
pulisher
May 15, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Shares Purchased by Barclays PLC - Defense World

May 15, 2025
pulisher
May 14, 2025

Gyre Therapeutics Reports Q1 2025 Financial Results - MSN

May 14, 2025
pulisher
May 14, 2025

Wells Fargo & Company MN Has $49,000 Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

May 14, 2025
pulisher
May 13, 2025

GYRE Makes Bullish Cross Above Critical Moving Average - Nasdaq

May 13, 2025
pulisher
May 12, 2025

1 Stock to Buy Hand Over Fist as ‘Risk On’ Sentiment Gains Momentum - The Globe and Mail

May 12, 2025
pulisher
May 11, 2025

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Here’s Why - Defense World

May 11, 2025
pulisher
May 09, 2025

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 09, 2025
pulisher
May 09, 2025

Gyre Therapeutics Reports Q1 2025 Revenue of $22.1 Million and Progress in Clinical Development and Commercialization Efforts - Nasdaq

May 09, 2025
pulisher
May 09, 2025

Earnings Flash (GYRE) Gyre Therapeutics Reports Q1 Revenue $22.1M, vs. FactSet Est of $28.4M - marketscreener.com

May 09, 2025
pulisher
May 07, 2025

Taking A Look At Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE - simplywall.st

May 07, 2025
pulisher
May 07, 2025

A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity - Yahoo Finance

May 07, 2025
pulisher
May 05, 2025

Gyre Therapeutics Inc expected to post earnings of 3 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 02, 2025

GYREGyre Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

May 02, 2025
pulisher
Apr 30, 2025

GNI Group Confirms NDA Timeline for Hydronidone - TipRanks

Apr 30, 2025
pulisher
Apr 17, 2025

VOO ETF News, 4/17/2025 - The Globe and Mail

Apr 17, 2025
pulisher
Apr 14, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Apr 14, 2025
pulisher
Apr 09, 2025

GYRE Stock Plummets to 52-Week Low at $6.15 Amid Market Challenges - Investing.com Canada

Apr 09, 2025
pulisher
Apr 07, 2025

Is Google Stock a Buy, Sell, or Hold on Potential CoreWeave GPU Deal? - The Globe and Mail

Apr 07, 2025
pulisher
Apr 02, 2025

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Benzinga

Apr 02, 2025
pulisher
Apr 01, 2025

Celcuity Stock (CELC) Dips Despite Promising Cancer Treatment in Pipeline - The Globe and Mail

Apr 01, 2025
pulisher
Mar 31, 2025

GYRE Stock Hits 52-Week Low at $8.26 Amid Market Challenges - Investing.com UK

Mar 31, 2025
pulisher
Mar 31, 2025

Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Gyre Therapeutics announces NMPA approval for trial on pirfenidone - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Major Breakthrough: Gyre's Cancer Drug Trial Targets 25% of Radiation Therapy Patients - Stock Titan

Mar 31, 2025
pulisher
Mar 30, 2025

Bank of New York Mellon Corp Has $168,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World

Mar 30, 2025
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):